Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 141 participants.

Also called NCT02577016

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 141 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02577016
Other papers using this trial's data
  • A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin Diabetes, obesity & metabolism, 2021-06 DOI, PubMed 33565686, PMC8248366 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02577016. Randomized; double masking; primary purpose treatment. Start 2015-11-05 (actual); primary completion 2016-11-18 (actual). Results posted on 2018-03-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo
Intervention (Drug)
Ipragliflozin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02577016
Content hash
96c9a171906815027fdc7f9074c63af2f9c19bf09494885b74155963eeb2bfec